To evaluate the effect of garlic tablet on metabolic syndrome in PCOS patients : A Randomized Double-blind Placebo-controlled Trial

Phase 2

• Conditions: Metabolic syndrome in PCOS patients.

• Registration Number: IRCT20150905023897N4
• Lead Sponsor: Tarbiat modares University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

People are willing to participate in the study
fertility age between 15-49 years
Iranian women
no pregnancy
have at least literacy for read and write
no Mellitus Diabets according to primary FBS
no chronic and coagulation disorders
lack of consumption Anti lipids and Anti hypertensive and anti coagulative drugs
no consuming garlic in a daily diet more than one cubit

Exclusion Criteria

People with drug side effects.Individuals unwilling to continue to participate in the study failure to comply with treatment protocol

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of Triglyceride. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Level of cholesterol. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Blood level of HDL. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Blood level of FBS. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Level of systolic and diastolic blood pressure. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Use of mercury barometer.;Waist to hip ratio. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Use of meter.

Secondary Outcome Measures

Name	Time	Method
evel of CRP. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Blood biochemistry test.;Menstrual dysfunction such as: Oligomenorrhea and amenorrhea. Timepoint: First of study and 8 weeks after intervention. Method of measurement: patient statements.;Clinical hyperandrogenemia. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Blood biochemistry test and clinical symptom.;Ultrasound view of the ovaries. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Use of ultrasound.;Sexual function. Timepoint: First of study and 8 weeks after intervention. Method of measurement: FSFI questionnaire.;Quality Of life. Timepoint: First of study and 8 weeks after intervention. Method of measurement: MPCOSQ questionnaire.